3SBIO(01530.HK)

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides Remitch, a nalfuraphine hydrochloride orally disintegrating tablets; MN709, a minoxidil foam formulation for the treatment of androgenetic alopecia and alopecia areata; and other products in the areas of nephrology, hematology, oncology, auto-immune, ophthalmology, and dermatology and metabolism.